Clinical features,outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a case-control study

Abstract

Objective

The objective of this paper is to investigate the clinical features, outcomes, and risk factors for posterior reversible encephalopathy syndrome (PRES) in systemic lupus erythematosus (SLE).

Methods

From 2011 to October 2017, SLE patients with PRES were identified from the First Affiliated Hospital of Zhengzhou University, China. Patients presenting with neuropsychiatric lupus hospitalized in the same period were included as controls. Additionally, survival status was acquired via telephone follow-up in March 2018.

Results

Thirty episodes of PRES were identified in 29 SLE patients from a total of 7059 SLE patients (prevalence 0.43%). Patients with PRES had a younger age at onset than controls, with seizures more commonly the initial clinical manifestation (80.00% vs 42.37%, p = 0.001). Multiple logistic regression yet again confirmed several known risk factors, including younger age (odds ratio (OR) 1.15 (95% confidence interval (CI) 1.13–1.16)), nephritis (OR 20.74 (18.10–23.75)), history of hypertension (OR 1.17 (1.05–1.31)), SLE Disease Activity Index without neurologic symptoms (SLEDAI-N) score >12 (OR 1.14 (1.11–1.18)) and eclampsia (OR 9.38 (7.84–11.23)). Furthermore, we identified two novel independent risk factors for PRES in SLE: white blood cells >9 × 10⁹/l (OR 2.33 (2.05–2.64)) and heart failure (OR 2.10 (1.18–2.42)). At follow-up, SLE patients with PRES had higher mortality than controls (30.77% vs 8.33%, respectively, p = 0.012).

Conclusions

PRES may be a reversible neurological deficit in patients with SLE other than neuropsychiatric lupus. Our results indicate two new risk factors for PRES and that PRES is associated with a higher mortality rate.

Keywords

Clinical features outcome posterior reversible encephalopathy syndrome risk factors systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Hinchey

Chaves

Appignani

et al.

A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494–500.

Bartynski

Boardman

. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007; 28: 1320–1327.

Fugate

Rabinstein

. Posterior reversible encephalopathy syndrome: Clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 2015; 14: 914–925.

Bartynski

. Posterior reversible encephalopathy syndrome, part 1: Fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008; 29: 1036–1042.

Fugate

Claassen

Cloft

Kallmes

Kozak

Rabinstein

. Posterior reversible encephalopathy syndrome: Associated clinical and radiologic findings. Mayo Clin Proc 2010; 85: 427–432.

Baizabal-Carvallo

Barragán-Campos

Padilla-Aranda

et al.

Posterior reversible encephalopathy syndrome as a complication of acute lupus activity. Clin Neurol Neurosurg 2009; 111: 359–363.

Tajima

Matsumoto

. Reversible posterior leukoencephalopathy syndrome in p-ANCA-associated vasculitis. Intern Med 2006; 45: 1169–1171.

Jung

Moon

Kwok

et al.

Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: Risk factors and clinical outcome. Lupus 2013; 22: 885–891.

Lai

Chen

Chang

et al.

Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013; 65: 1766–1774.

10.

West

. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20: 129–158.

11.

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.

12.

Liu

Zhang

et al.

Posterior reversible encephalopathy syndrome could be an underestimated variant of “reversible neurological deficits” in systemic lupus erythematosus. BMC Neurol 2012; 12: 152–152.

13.

Budhoo

Mody

. The spectrum of posterior reversible encephalopathy in systemic lupus erythematosus. Clin Rheumatol 2015; 34: 2127–2134.

14.

Damrongpipatkul

Oranratanachai

Kasitanon

Wuttiplakorn

Louthrenoo

. Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: A case-control study. Clin Rheumatol 2018; 37: 691–702.

15.

Merayo-Chalico

Apodaca

Barrera-Vargas

et al.

Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: A multicentric case-control study. J Neurol Neurosurg Psychiatry 2016; 87: 287–294.

16.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

17.

Bortoluzzi

Scirè

Bombardieri

et al.

Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford) 2015; 54: 891–898.

18.

Fujieda

Kataoka

Odani

et al.

Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus. Mod Rheumatol 2011; 21: 276–281.

19.

Schwartz

. Hyperperfusion encephalopathies: Hypertensive encephalopathy and related conditions. Neurologist 2002; 8: 22–34.

20.

Rabinstein

Mandrekar

Merrell

Kozak

Durosaro

Fugate

. Blood pressure fluctuations in posterior reversible encephalopathy syndrome. J Stroke Cerebrovasc Dis 2012; 21: 254–258.

21.

Porcello Marrone

Gadonski

de Oliveira Laguna

et al.

Blood-brain barrier breakdown in reduced uterine perfusion pressure: A possible model of posterior reversible encephalopathy syndrome. J Stroke Cerebrovasc Dis 2014; 23: 2075–2079.

22.

Dong

Bai

Nao

. Clinical and radiological features of posterior reversible encephalopathy syndrome in patients with pre-eclampsia and eclampsia. Clin Radiol 2017; 72: 887–895.

23.

Chen

Lee

Tsui

. MR imaging findings of medulla oblongata involvement in posterior reversible encephalopathy syndrome secondary to hypertension. AJNR Am J Neuroradiol 2009; 30: 755–757.

24.

Marra

Vargas

Striano

Del Guercio

Buonanno

Servillo

. Posterior reversible encephalopathy syndrome: The endothelial hypotheses. Med Hypotheses 2014; 82: 619–622.

25.

Dardis

Craciun

Schell

. Posterior reversible encephalopathy syndrome in the setting of COPD: Proposed pathogenesis. Med Hypotheses 2013; 80: 197–200.

26.

Kuryliszyn-Moskal

Klimiuk

Sierakowski

Ciołkiewicz

. Vascular endothelial growth factor in systemic lupus erythematosus: Relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Arch Immunol Ther Exp (Warsz) 2007; 55: 179–185.

27.

Robak

Sysa-Jedrzejewska

Robak

. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm 2003; 12: 293–298.

28.

Lee

Dickson

Liu

Brosnan

. Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma. J Neuroimmunol 1993; 46: 19–24.

29.

Chou

Lai

Yeh

et al.

Posterior reversible encephalopathy syndrome: Magnetic resonance imaging and diffusion-weighted imaging in 12 cases. Kaohsiung J Med Sci 2004; 20: 381–388.

30.

Liman

Bohner

Endres

Siebert

. Discharge status and in-hospital mortality in posterior reversible encephalopathy syndrome. Acta Neurol Scand 2014; 130: 34–39.

31.

Burnett

Hess

Roberts

Bass

Douglas

Josephson

. Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors. Clin Neurol Neurosurg 2010; 112: 886–891.

32.

Legriel

Schraub

Azoulay

et al.

Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One 2012; 7: e44534–e44534.